Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Preferred Shares (2025 - 2026)

Heron Therapeutics filings provide 2 years of Preferred Shares readings, the most recent being $1.0 million for Q1 2026.

  • On a quarterly basis, Preferred Shares changed N/A to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a N/A change, with the full-year FY2025 number at $1.0 million, changed N/A from a year prior.
  • Preferred Shares hit $1.0 million in Q1 2026 for Heron Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $7.9 million in Q3 2025 to a low of $1.0 million in Q4 2025.